SATELLOS BIOSCIENCE INC

MSLENASDAQ

🏆 #4356 by market capEarnings Aug 12US Equity

$10.00▼ $0.02 (−0.20%)

Live

1h—

24h▼ 0.2%

7d▼ 1.1%

14d▲ 4.5%

30d▲ 9.8%

1y—

🏦Market Cap

$13M

Small Cap

📈Revenue Growth (YoY)

+0.0%

Slowing

📊Gross Margin

0.0%

Thin

💵FCF Margin

0.0%

Thin

⚖️P/S Ratio

0.0x

Cheap

Otter Score

Weak

Trading Snapshot

Day Range: $9.95 – $10.16
52-Week Range: $4.85 – $13.40
Volume: $1.73B
Avg Volume: $2.26B
Shares Outstanding: 1.3M
Next Earnings: Oct 13, 2026

Fundamentals Snapshot

Annual Revenue: $940,324
Last Q Revenue: $232,896
P/E Ratio: -1.8
P/S Ratio: 0.0x
EPS (TTM): $-0.32
Dividend Yield: 0.00%

Why Investors Own MSLE

✓High-growth profile — revenue up +17.6% YoY with expanding US Equity exposure.
✓Healthy economics — 67% gross margin and 6% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$940,324▲ +19.9% YoY

Gross Margin (TTM)

67.3%▲ +2.7% YoY

Operating Income (TTM)

$157,974▲ +19.9% YoY

Free Cash Flow (TTM)

$53,598▲ +19.9% YoY

About SATELLOS BIOSCIENCE INC

Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.

🦦